A bipartisan group of legislators has introduced the ASAP Act, a new piece of legislation designed to expand Medicare coverage for blood-based biomarker tests used to detect Alzheimer’s disease and other forms of dementia. Currently, access to these diagnostic tools is limited for many Medicare beneficiaries, and proponents argue that federal coverage is necessary to ensure patients can receive early, accurate diagnoses.

The proposed bill focuses on authorizing the Centers for Medicare & Medicaid Services (CMS) to provide coverage for tests that have already received FDA approval. Supporters of the bill emphasize that early detection is critical for patient care, as it allows individuals to access treatments and support services sooner. By streamlining the path to coverage, the legislation intends to remove financial barriers that currently prevent many seniors from accessing advanced diagnostic technology.

While the bill is presented as a rare point of consensus in a polarized political climate, the legislative path forward remains to be seen. The proposal highlights a growing focus on addressing the rising prevalence of Alzheimer’s as the U.S. population ages. No significant opposition to the core goal of the bill has been reported, though the specific budgetary impact of expanding Medicare coverage to include these tests will likely be a subject of debate as the bill moves through the committee process.